See more : Indiabulls Real Estate Limited (IBREALEST.NS) Income Statement Analysis – Financial Results
Complete financial analysis of Anhui Sunhere Pharmaceutical Excipients Co.,Ltd. (300452.SZ) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Anhui Sunhere Pharmaceutical Excipients Co.,Ltd., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Yonz Technology Co Ltd (603381.SS) Income Statement Analysis – Financial Results
- Arcadia Biosciences, Inc. (RKDA) Income Statement Analysis – Financial Results
- Erdene Resource Development Corporation (ERDCF) Income Statement Analysis – Financial Results
- Plains All American Pipeline, L.P. (PAA) Income Statement Analysis – Financial Results
- Holcim Ltd (HOLN.SW) Income Statement Analysis – Financial Results
Anhui Sunhere Pharmaceutical Excipients Co.,Ltd. (300452.SZ)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.shanhe01.com
About Anhui Sunhere Pharmaceutical Excipients Co.,Ltd.
Anhui Sunhere Pharmaceutical Excipients Co.,Ltd. manufactures and sells pharmaceutical excipients and professional medicines in China. The company provides cellulose, starch, povidone, stearic acid, coating powder, resin, food additive, and other products. It also exports its products to Europe, the United States, Southeast Asia, and internationally. Anhui Sunhere Pharmaceutical Excipients Co.,Ltd. is based in Huainan, China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 839.26M | 704.53M | 616.71M | 531.20M | 464.07M | 428.56M | 339.36M | 286.40M | 258.92M | 239.39M | 212.89M | 183.88M | 143.23M |
| Cost of Revenue | 573.29M | 494.76M | 438.53M | 366.76M | 294.52M | 283.21M | 234.44M | 189.59M | 169.22M | 162.78M | 139.18M | 117.86M | 97.69M |
| Gross Profit | 265.97M | 209.77M | 178.18M | 164.44M | 169.54M | 145.35M | 104.92M | 96.81M | 89.70M | 76.61M | 73.71M | 66.02M | 45.54M |
| Gross Profit Ratio | 31.69% | 29.77% | 28.89% | 30.96% | 36.53% | 33.92% | 30.92% | 33.80% | 34.64% | 32.00% | 34.62% | 35.91% | 31.80% |
| Research & Development | 41.95M | 34.43M | 26.80M | 18.12M | 16.19M | 14.20M | 8.60M | 7.98M | 7.34M | 6.98M | 6.60M | 7.51M | 0.00 |
| General & Administrative | 5.78M | 5.27M | 8.40M | 5.46M | 5.23M | 4.20M | 3.82M | 3.62M | 2.72M | 2.50M | 2.27M | 2.55M | 10.29M |
| Selling & Marketing | 28.66M | 23.28M | 21.38M | 20.54M | 37.17M | 34.22M | 27.48M | 23.04M | 21.59M | 19.81M | 18.21M | 16.25M | 11.07M |
| SG&A | 34.44M | 28.55M | 29.78M | 26.00M | 42.40M | 38.43M | 31.30M | 26.66M | 24.31M | 22.31M | 20.48M | 18.80M | 21.36M |
| Other Expenses | 4.13M | 125.88K | -3.03M | -1.79M | -404.75K | 2.03M | 1.79M | 3.51M | 4.43M | 5.55M | 2.01M | 4.02M | 1.74M |
| Operating Expenses | 80.53M | 80.64M | 79.04M | 57.97M | 70.59M | 62.61M | 49.83M | 47.97M | 44.77M | 41.33M | 34.64M | 32.59M | 22.24M |
| Cost & Expenses | 653.82M | 575.40M | 517.57M | 424.72M | 365.11M | 345.82M | 284.27M | 237.56M | 213.99M | 204.11M | 173.82M | 150.45M | 119.93M |
| Interest Income | 919.41K | 1.32M | 849.35K | 574.90K | 607.56K | 619.14K | 1.43M | 1.89M | 600.05K | 310.43K | 266.82K | 325.02K | 0.00 |
| Interest Expense | 4.30M | 1.21M | 1.20M | 728.39K | 84.33K | 500.26K | 1.02M | 1.82M | 151.08K | 73.22K | 13.80K | 49.54K | 0.00 |
| Depreciation & Amortization | 39.07M | 36.19M | 34.68M | 31.76M | 19.68M | 16.11M | 13.53M | 11.81M | 10.97M | 10.02M | 4.77M | 3.04M | 44.43K |
| EBITDA | 229.57M | 173.68M | 132.95M | 139.65M | 123.23M | 98.85M | 68.60M | 69.03M | 62.93M | 50.86M | 45.57M | 36.47M | 23.58M |
| EBITDA Ratio | 27.35% | 25.06% | 22.22% | 26.20% | 26.57% | 23.24% | 20.24% | 21.34% | 24.40% | 21.39% | 21.54% | 20.04% | 16.46% |
| Operating Income | 185.44M | 136.28M | 99.71M | 108.96M | 103.69M | 88.37M | 60.77M | 53.83M | 47.71M | 35.31M | 38.88M | 33.43M | 23.54M |
| Operating Income Ratio | 22.10% | 19.34% | 16.17% | 20.51% | 22.34% | 20.62% | 17.91% | 18.80% | 18.43% | 14.75% | 18.27% | 18.18% | 16.43% |
| Total Other Income/Expenses | 375.15K | 125.88K | -3.03M | -1.79M | -451.87K | 2.03M | 1.79M | 3.39M | 4.10M | 5.46M | 1.90M | 3.90M | 1.73M |
| Income Before Tax | 185.82M | 136.40M | 96.68M | 107.17M | 103.24M | 90.39M | 62.56M | 57.04M | 51.81M | 40.77M | 40.79M | 37.32M | 25.26M |
| Income Before Tax Ratio | 22.14% | 19.36% | 15.68% | 20.18% | 22.25% | 21.09% | 18.44% | 19.92% | 20.01% | 17.03% | 19.16% | 20.30% | 17.64% |
| Income Tax Expense | 21.20M | 5.47M | 11.14M | 13.65M | 13.07M | 13.19M | 9.68M | 8.26M | 7.53M | 5.84M | 5.77M | 5.16M | 3.42M |
| Net Income | 161.54M | 130.71M | 89.25M | 93.94M | 84.37M | 70.11M | 50.34M | 48.79M | 44.27M | 34.93M | 35.02M | 32.16M | 21.84M |
| Net Income Ratio | 19.25% | 18.55% | 14.47% | 17.69% | 18.18% | 16.36% | 14.83% | 17.03% | 17.10% | 14.59% | 16.45% | 17.49% | 15.25% |
| EPS | 0.69 | 0.56 | 0.38 | 0.41 | 0.36 | 0.30 | 0.21 | 0.21 | 0.20 | 0.20 | 0.20 | 0.18 | 0.12 |
| EPS Diluted | 0.67 | 0.56 | 0.38 | 0.41 | 0.36 | 0.30 | 0.21 | 0.21 | 0.20 | 0.20 | 0.20 | 0.18 | 0.12 |
| Weighted Avg Shares Out | 234.11M | 233.41M | 234.61M | 230.43M | 233.37M | 235.25M | 235.25M | 233.34M | 224.46M | 177.11M | 175.80M | 177.25M | 175.80M |
| Weighted Avg Shares Out (Dil) | 241.10M | 233.41M | 234.61M | 230.43M | 233.37M | 236.97M | 236.30M | 233.34M | 224.46M | 177.11M | 175.80M | 177.25M | 175.80M |
Source: https://incomestatements.info
Category: Stock Reports